博福特韦是一种靶向新冠病毒3C 样蛋白酶的小分子抑制剂, 具有注射和雾化吸入两种给药形式,
可单药给药, 不需要联用肝药酶抑制剂. 目前数据显示, 博福特韦具有广谱抗冠状病毒活性 …

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
sometimes referred to as the novel coronavirus (2019-nCoV), is currently a worldwide threat …

The rapid growth of COVID-19 cases is causing an increasing death toll and also paralyzing
the world economy. De novo drug discovery takes years to move from idea and/or pre-clinic …

新型冠状病毒肺炎(COVID-19) 疫情在全球大流行, 临床上迫切需要特异性抗病毒治疗药物.
对已批准上市或正在临床开发的药物开展重定位研究是针对突发疫情快速寻找潜在治疗药物 …

Boceprevir is an HCV NSP3 inhibitor that was explored as a repurposed drug for COVID-19.
It inhibits the SARS-CoV-2 main protease (M Pro) and contains an α-ketoamide warhead, a …

Introduction At this time, there is no specific therapeutic or vaccine for treatment of the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Hence, available drugs for …

Favipiravir, developed by Japanese researchers as a treatment for influenza and other RNA
viral infections, in 2020-2022, has become extensively used in Russia, China, India, Turkey …

Since the outbreak of the novel coronavirus (SARS-CoV-2) disease COVID-19 (also known
as 2019-nCoV) caused by SARS-CoV-2 in the end of 2019, it has spread rapidly in …

The main protease (Mpro) of the betacoronavirus SARS-CoV-2 is an attractive target for the
development of treatments for COVID-19. Structure-based design is a successful approach …

Purpose In the wake of SARS-CoV-2's global spread, human activities from health to social
life to education have been affected. Favipiravir and Molnupiravir exhibited novel …